Summary RAP-5, a monoclonal antibody raised against a p2l"as peptide, has been claimed to show immunohistochemical localisation of cells with infiltrative properties in human tumours. We confirmed that this antibody reveals pronounced cellular heterogeneity in human colonic neoplasms but could find no obvious relationship to infiltrative activity. bound to many different cell types, neoplastic and normal. In order to clarify the specificities of RAP-5 we applied it to two cell lines: nontumorigenic hamster fibroblasts in which ras expression is barely detectable, and a vigorously tumorigenic line derived from these fibroblasts by insertion of the human mutated Ha-ras oncogene in a high expression vector. Another antibody to p2l"as, Y13-259, clearly distinguished between these cell lines both on immunoblots and immunocytochemically, but RAP-5 did not. Rather, it bound to proteins of a variety of molecular weights in both cell lines. The results show that RAP-5 is unlikely to be a useful reagent for detection of ras associated proteins in human tissues.
Although the mutated form of the human Harvey ras oncogene was the first transforming gene of cellular origin to be identified (Der et al., 1982; Parada et al., 1982; Santos et al., 1982) , the precise role of ras oncogenes in human malignancy is far from established. Ras genes code for a 21,000 dalton protein, p2lras, which is located on the inner face of the plasma membrane (Shih et al., 1979; Willingham et al., 1980 Willingham et al., , 1983 , binds GTP and possesses GTPase activity Gibbs et al., 1984; McGrath et al., 1984) . Mutations in the vicinity of codons 12 and 61 of the ras genes lead to products deficient in GTPase, but not GTP binding activity, and these products in particular have been associated with carcinogenesis. Thus, insertion of mutated ras genes into cultured cells confers upon them a transformed phenotype and tumorigenicity in animals (Reddy et al., 1982; Tabin et al., 1982; Taparowski et al., 1982) ; mutant p21ras introduced to cells by micro-injection can also initiate proliferation and effect transient phenotypic changes akin to transformation Stacey & Kung, 1984) ; and ras gene mutation at the critical sites has been shown to be an early event in experimental chemical carcinogenesis (Sukumar et al., 1983; Balmain et al., 1984) . In around 15% of human solid tumours, there is evidence for the presence of mutated ras genes (reviewed by Weinberg, 1985 Amplification of ras genes has also been recorded in such tumours, although it is rare (Pulciani et al., 1985) . Hyperexpression of ras mRNA, and raised levels of p2lras (without necessarily implicating mutation of the gene) have been reported in primary human tumours in a variety of sites (Slamon et al., 1984; Spandidos and Agnantis, 1984; Spandidos et al., 1985; Tanaka et al., 1986; Kurzrock et al., 1986) . Some studies suggest that ras expression increases in parallel with aggressive behaviour in neoplasms of the human colon , breast (Ohuchi et al., 1986) and prostate (Viola et al., 1986) , but the opposite result has also been reported (Spandidos & Kerr, 1984; Gallick et al., 1985; Williams et al., 1985; Kerr et al., 1986) .
Recently, a series of monoclonal antibodies termed RAP1-5 has been raised against a synthetic peptide, consisting of amino acids 10 -17 of mutated humans Ha-ras p21. In immunohistochemical studies, these antibodies were claimed to show striking preferential localisation to infiltrative carcinoma cells, as compared to noninfiltrative neoplasms and normal tissues. In this paper, we examine the reactivity of RAP-5 with a range of normal and pathological human tissues, and with rodent cells lines in which widely divergent levels of expression of human Ha-ras p21 had been achieved through genetic manipulation (Spandidos & Wilkie, 1984 (Furth et al., 1982; Lacal & Aaronson, 1986) , to be particularly helpful in assessing the important claims made for this new antibody.
Materials and methods
Fibroblast cell lines CHL and FHO5Tl were maintained in vitro as described previously (Spandidos & Wilkie, 1984) . CHL cells were originally obtained by culture of fibroblasts from Chinese hamster lung. FH05TI cells were derived from CHL cells by transfection with the plasmid pHO5Tl, which contains the mutated human Ha-ras (T24 bladder carcinoma cell line) oncogene adjacent to the SV40 transcriptional enhancer sequence. Cytocentrifuge preparations were made from these cells after disruption of the monolayers by gentle treatment with EDTA and trypsin.
Human colorectal tissues Tissues were obtained within minutes of surgical removal. Some portions were immediately frozen in liquid nitrogen and stored at -80°C prior to preparation of cryostat sections, whilst others were fixed in 4% neutral buffered formaldehyde at room temperature for processing in paraffin. In all, frozen material was studied from normal colonic mucosa (5 cases), colorectal adenomas (6) and adenocarcinomas (6). Material from the 6 adenocarcinomas was also processed in paraffin. For comparison, formaldehyde fixed paraffin processed material representing other normal and pathological tissues was selected from departmental files: tonsil (1), intradermal naevus (1), malignant melanoma of skin (1), and bronchial carcinoid tumour (1).
Immunocytochemistry
Immunocytochemical analysis with RAP-5 and Y13-259 was carried out on 5,um cryostat sections fixed for 15 min in either 4% neutral buffered formaldehyde or acetone, using a streptavidinbiotin immunoperoxidase method as described previously . With RAP-5, the same techniques were also applied to dewaxed, rehydrated paraffin sections. Briefly, sections or cytocentrifuge preparations were washed in Tris buffered saline, (TBS -sodium chloride 150 mm, Tris HCl 10mm, pH 7.6) and nonspecific binding blocked by application of 10% normal rabbit serum in TBS (NR-TBS). The primary antibody was applied for 30 min at room temperature at the optimum dilution in NR-TBS. For RAP-5 this dilution lay between 1:10,000 and 1:20,000, whilst for Y13-259 the optimum dilution for use with tissue sections was 1:100 and with cytocentrifuge preparations 1: 500. The sections were washed in TBS, and incubated for 30 min at room temperature in the second antibody. For RAP-5, this was sheep anti-mouse immunoglobulin (Amersham International) and for Y13-259 goat anti-rat immunoglobulin (Sigma), both biotinylated and diluted 1:50 in NR-TBS. After further washing in TBS the sections were incubated for 15 min with streptavidin-biotinylated horseradish peroxidase complex (Amersham) diluted 1:200 in NR-TBS. The reaction was developed after a final wash in TBS, with diaminobenzidine solution (1 mgml-1) (BDH) in 50mM Tris HCl pH 7.6, containing 10mM imidazole activated immediately prior to use with H202' The sections were briefly counterstained with haematoxylin, dehydrated and mounted.
Negative controls were included for each case, consisting of sections treated identically to the others but with NR-TBS replacing the primary antibody. Invariably, these gave no immunoperoxidase reaction save over macrophages and polymorphonuclear leukocytes within the tissues.
Immunoblots
These were prepared from lysates of CHL and FHO5T1 cells. Washed cell pellets were lysed in 100mM sodium chloride, 10mM Tris pH7.5, 0.1% SDS, 1% NP40 at 40C. Insoluble residue was removed by centrifugation at 30,000 g for 30 min and the supernatants were denatured by heat immediately prior to electrophoresis. Approximately 20jug of protein was loaded per track on 15% polyacrylamide gels, blotted on nitrocellulose, and detected by Indian ink (Hancock & Tsung, 1983) , or immunostaining. We used essentially the same conditions for immunostaining of the nitrocellulose filter as for the cytological preparations, with the exception that the antibody dilutions used were 1:100 and 1:1000 for both Y13-259 and RAP-5. Incubation was for 2 h at room temperature.
Results
Binding of RAP-5 and Y13-259 to human tissue sections We confirmed, in the present series of experiments, our previous results on the staining pattern of Y13-259 on acetone-fixed frozen sections of human colorectal tissues. Normal mucosa and the epithelium of most adenocarcinomas showed low levels of reactivity, whilst in general adenomas showed staining of greater intensity. We did not observe specific staining in nonepithelial cell types.
EVALUATION OF AN ANTIBODY TO RAS PEPTIDE 879
RAP-5, applied to formaldehyde-fixed frozen sections of the same and other blocks showed a different pattern: although normal epithelium tended to stain at low levels, there were no consistent differences between infiltrative and noninfiltrative neoplasms. Infiltrative carcinomas sometimes showed a moderate reaction, but sometimes were negative, whilst non-infiltrative lesions also gave positive reactions. Within individual tumours there was considerable variation in the distribution of positively staining cells, and in the intensity of the reaction (Figure la,b) . We frequently observed moderate staining of the muscularis propria. Serosal mesothelium also consistently gave a strong reaction. In formaldehyde-fixed paraffin and frozen sections of a variety of other tissues, RAP-5 gave strongly positive reactions, notably in the cells of an intradermal naevus, malignant melanoma, and carcinoid tumour, but there was no obvious relationship with aggressive activity (Figure 2a-c) . Although only single cases of these conditions were studied, the results indicate that reactivity to RAP-5 is not restricted to epithelial cells or to cells originating from any one germ layer. Binding of RAP-S and Y13-259 to proteins in ras-expressing cell lines As previously reported , Y13-259 applied to acetone fixed cytocentrifuge preparations of the ras-transformed cell line FHOSTI, yielded strong immunochemical staining over all cells (Figure 3a) , whereas less than 5% of the parental, untransformed CHL fibroblasts gave positive reactions. Analysis of the antibody binding proteins on immunoblots, after SDS-polyacrylamide gel electrophoresis, confirmed that Y13-259 at both 1: 100 and 1: 1000 dilution detected a single protein, of apparent mol. wt 21 kd in FHO5TI cells ( Figure  4a ). In extracts of CHL cells the same binding protein was either undetectable or present in much reduced quantity. Indian ink staining of the nitrocellulose blots, or staining of unblotted polyacrylamide gels with kenacid blue showed that in terms of proteins identifiable by these means the extracts from FHOSTI and CHL cells were closely similar.
In contrast with these results, immunocytochemistry using RAP-5 as the primary antibody revealed no differences between the CHL and FHOST1 cells (Figure 3b, c) . All cells of either type were negative after acetone fixation, but after fixation in formaldehyde gave strongly positive staining over a wide range of dilutions down to 1: 20,000. Analysis of the antibody binding proteins was attempted on immunoblots. At dilutions of 1: 1000 RAP-S scarcely defined discrete protein bands in gel tracks loaded with extracts of either CHL or FHOSTI cells (Figure 4b ). At tenfold higher concentration, a number of proteins of a wide range of molecular size appeared to bind to the antibody; the majority of these were present in similar quantity in FHOSTI and CHL extracts (Figure 4c ). Discussion RAP-S is secreted by a hybridoma derived from spleen cells of a mouse immunised with a ras octapeptide linked to thyroglobulin . The octapeptide had the amino acid sequence 10 -17 of the mutated human (T24) Haras p21, and selection of the hybridoma was based upon preferential binding of its immunoglobulin to the mutated as opposed to the non-mutated peptide. In practice, however, RAP-5 was found by its originators to detect epitopes present in a far higher proportion of human tumours than are associated with transforming mutations of the ras gene family. It was assumed that cross-reaction with non-mutated p21 was responsible. Specificity of RAP-5 for p21 ras was adduced from competition binding studies and from immunoblots, although the concentrations of antibody used in the latter were unexpectedly high. Published data on RAP-5 do not yet include studies on a wide range of neoplastic and normal tissues. The major interest in this new antibody derived from the observation that it detected heterogeneity within human breast, colonic and prostatic neoplasms, preferentially staining areas showing infiltration of adjacent tissues, provided it was applied to sections fixed in formaldehyde Viola et al., 1985 Viola et al., , 1986 Ohuchi et al., 1986 ). There were obvious implications of great fundamental and practical importance in this suggestion.
The data presented in this paper demonstrate the value of unequivocal biological test systems for such novel and potentially exciting reagents. FHO5TI cells and the parental CHL fibroblast line differ from one another in the possession of a mutated Ha-ras gene, in expression of the gene at the level of transcription (a feature which we confirmed in dot blots of RNA extracted from cells of similar passage history to those described here), in expression of a protein with the molecular size expected of p2lras, in availability of this protein for detection by immunocytochemical methods, and in the ability to generate rapidly growing aggressive tumours in immune suppressed animals (Spandidos & Wilkie, 1984; Spandidos, 1985 described by its originators, it seemed to detect proteins plentiful in both cells, and also in many human cell types, both normal and neoplastic, of a variety of embryological derivations. These results do not exclude the possibility that RAP-5 may bind to a ras peptide, but indicate that it also recognises other widely distributed epitopes which are not related to ras expression. A similar conclusion has recently been reached on the basis of immunohistochemical studies on human breast tissue (Ghosh et al., 1986) . Other antibodies raised against small oncogene peptides have been shown in the past to be capable of reaction with epitopes common to many cellular proteins despite the appearances of specificity in immunoabsorption studies (Nigg et al., 1982) .
The role of ras products in tumour aggression remains undecided. In experimental animals, cells transformed by the mutated ras gene have been shown to be capable of both infiltration and metastasis (Spandidos & Wilkie, 1984; Muschel et al., 1985; Thorgeirsson et al., 1985) , but ras expression does not always confer aggressive properties. Normal ras genes are expressed physiologically in non-dividing tissues (Spandidos & Dimitrov, 1985) , and in one phaeochromocytoma cell line insertion of the products of the mutated ras gene led to differentiation and replication arrest (Bar-Sagi & Feramisco, 1985) . Several different groups have presented evidence from animal tumours and human colonic neoplasia that activation (by mutation or hyperexpression) of the ras gene is a feature of early rather than late neoplasia (Sukumar et al., 1983; Balmain et al., 1984; Williams et al., 1985; Yuspa et al., 1985) .
It seems probable that immunohistochemical methods will remain important in attempts to clarify the role of ras and other oncogenes in human neoplasia. This paper highlights the value of genetically modified cell lines in the critical evaluation of antibodies raised against oncogene proteins and peptides, and in particular casts serious doubt on the usefulness of RAP-5 in detection of human ras-coded, or ras-associated proteins.
